SLC5A2 and diabetic kidney disease: Dapagliflozin, the first SGLT-2 inhibitor approved for the treatment of type 2 diabetes (106), continues to demonstrate significant benefits in reducing renal and cardiovascular outcomes, as well as the risk of mortality in patients with stage G4 DKD.